EVI5

Across TCGA pan-cancer cohorts, EVI5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EVI5 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EVI5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EVI5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where EVI5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.485	1.000	.036	7	view →
LSCC	DFS	Tertile	II,III,IV	0.843	1.000	.015	6	view →
GBM	OS	Tertile	All	0.790	0.955	.015	4	view →
UCEC	DFS	Quartile	All	1.000	0.805	.007	4	view →
PDAC	OS	Quartile	All	0.986	0.808	.035	2	view →
LUAD	DFS	Tertile	All	0.942	0.882	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EVI5–CCRCC (OS)

Open the CCRCC breakdown →